Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
52.73m
Last Price
$5.30
52-Week Range
$3.53 - $10.48
09/04/2026 08:00 PM EDT